ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,187.70
0.13%
Dow Jones
38,884.26
0.00%
US Dollar vs MXN
16.92565
0.11%
Brent Oil
81.955
-1.10%
Bitcoin
62,305.54
-0.05%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Instill Bio Inc (TIL)

  7. Instill Bio Inc (TIL) Noticias

TIL

Instill Bio (TIL)

Instill Bio Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:TIL
FechaHoraFuenteTítuloSímboloCompañía
21/03/202416:00GlobeNewswire Inc.Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
14/02/202415:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TILInstill Bio Inc
13/02/202416:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TILInstill Bio Inc
16/01/202407:00GlobeNewswire Inc.Instil Bio Announces Strategic UpdateNASDAQ:TILInstill Bio Inc
05/12/202316:00GlobeNewswire Inc.Instil Bio Announces Effective Date of 1-for-20 Reverse Stock SplitNASDAQ:TILInstill Bio Inc
13/11/202316:27Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:TILInstill Bio Inc
13/11/202316:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TILInstill Bio Inc
13/11/202316:00GlobeNewswire Inc.Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
06/11/202306:00GlobeNewswire Inc.Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual MeetingNASDAQ:TILInstill Bio Inc
14/08/202306:00GlobeNewswire Inc.Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
26/06/202315:38GlobeNewswire Inc.Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual ConferenceNASDAQ:TILInstill Bio Inc
26/06/202315:33Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TILInstill Bio Inc
11/05/202306:00GlobeNewswire Inc.Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
28/04/202315:37Edgar (US Regulatory)Revised Proxy Soliciting Materials (definitive) (defr14a)NASDAQ:TILInstill Bio Inc
24/04/202315:31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:TILInstill Bio Inc
10/04/202308:38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:TILInstill Bio Inc
31/03/202306:40Edgar (US Regulatory)Annual Report (10-k)NASDAQ:TILInstill Bio Inc
31/03/202306:00GlobeNewswire Inc.Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
31/01/202316:00GlobeNewswire Inc.Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. SiteNASDAQ:TILInstill Bio Inc
20/01/202315:13Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:TILInstill Bio Inc
20/01/202315:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TILInstill Bio Inc
09/01/202306:00GlobeNewswire Inc.Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal CancerNASDAQ:TILInstill Bio Inc
12/12/202210:45Business WireNewman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)NASDAQ:TILInstill Bio Inc
08/12/202206:00GlobeNewswire Inc.Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in WorkforceNASDAQ:TILInstill Bio Inc
14/11/202215:07GlobeNewswire Inc.Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
08/11/202206:00GlobeNewswire Inc.Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual MeetingNASDAQ:TILInstill Bio Inc
31/10/202208:14TipRanksInstil Bio Pauses Clinical Trial EnrollmentsNASDAQ:TILInstill Bio Inc
31/10/202206:00GlobeNewswire Inc.Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to ManufacturingNASDAQ:TILInstill Bio Inc
18/10/202206:00GlobeNewswire Inc.Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung CancerNASDAQ:TILInstill Bio Inc
19/09/202206:20GlobeNewswire Inc.Instil Bio to Present at Jefferies Cell and Genetic Medicine SummitNASDAQ:TILInstill Bio Inc
 Showing the most relevant articles for your search:NASDAQ:TIL

Su Consulta Reciente

USOTC
RHHBY
Roche (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
FX
USDMXN
US Dollar vs MXN
NASDAQ
AAPL
Apple
AMEX
XLV
Health Care Select Sector
NYSE
XOM
Exxon Mobil
USOTC
BASFY
BASF (QX)
NYSE
KO
Coca Cola
CCOM
US500
US 500
NYSE
VZ
Verizon Communications
AMEX
XLF
Financial Select Sector
NYSE
CVX
Chevron
NYSE
MCD
McDonalds
FX
EURUSD
Euro vs US Dollar
COIN
BTCUSD
Bitcoin
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados